What's Happening?
Glaukos Corporation, a leader in ophthalmic pharmaceuticals and medical technology, is set to present multiple scientific abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS)
annual meeting in Washington, D.C. The company will highlight its advancements in glaucoma and corneal health, including the introduction of Epioxa, the first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment. Glaukos will also present data on its iDose TR, a long-duration intracameral pharmaceutical for glaucoma, and the iStent infinite Trabecular Micro-Bypass System. These presentations underscore Glaukos' commitment to advancing treatment options for chronic eye diseases.
Why It's Important?
Glaukos' participation in the ASCRS annual meeting highlights its role in pioneering new treatments for eye diseases, which could significantly impact patient care. The introduction of Epioxa and the data on iDose TR and iStent infinite represent potential breakthroughs in the management of glaucoma and corneal disorders. These innovations could improve patient outcomes by offering more effective and less invasive treatment options. The company's focus on novel therapies aligns with the growing demand for advanced medical solutions in ophthalmology, potentially influencing future treatment standards and expanding market opportunities for Glaukos.
